HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
Pharmaceuticals, Biotechnology and Life Sciences
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
CINCINNATI, Aug. 28, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical…
NEWARK, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing…
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company…
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023Data from the trial published simultaneously in JAMA CardiologyMavacamten demonstrated…
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the…
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA…
Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development,…
Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van…
– The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint…